Novartis & Sanofi
6 shared events · Importance 3 · Last updated Jul 29, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Novartis: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Sanofi: Sanofi is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
Novartis: A signatory of the open letter urging the European Union and member states to strengthen the region's pharmaceutical industry. The appeal is aimed at improving the investment and regulatory climate it operates in.
Sanofi: A signatory of the open letter calling on the European Union to boost pharmaceutical investment. The appeal reflects its concern about Europe lagging the United States and China in drug research and trials.
Sep 22, 2026 · 6 articles
Business
Novartis: Novartis participated in the symposium, demonstrating its commitment to green chemistry and sustainable manufacturing.
Sanofi: Sanofi participated in the symposium, reflecting its interest in sustainable manufacturing technologies.
Jul 20, 2026 · 6 articles
Business
Novartis: Novartis' Leqvio is another competitor in the PCSK9 inhibitor market. Scribe's progress may affect Novartis's competitive position.
Sanofi: Sanofi participated in a concurrent private placement, purchasing 500,000 shares for $7.5 million, and has a prior $1.5 billion research collaboration with Scribe. This deepens Sanofi's strategic involvement in gene editing and cardiovascular therapies.
Jul 06, 2026 · 25 articles
Business
Novartis: Dominant radiopharmaceutical player with Pluvicto and Lutathera faces a more vertically integrated competitor as Telix absorbs ITM's isotope supply and neuroendocrine tumor pipeline.
Sanofi: Named among recent radiopharmaceutical acquirers, underscoring competitive pressure in the sector that motivates Telix's vertical integration.
Sep 21, 2026 · 6 articles
Regulatory
Novartis: Novartis is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Novartis and Sanofi interact across events, view sentiment trends, and discover connected entities.
Open Dashboard